Quarterlytics / Healthcare / Medical - Care Facilities / Option Care Health

Option Care Health

opch · NASDAQ Healthcare
Claim this profile
Ticker opch
Exchange NASDAQ
Sector Healthcare
Industry Medical - Care Facilities
Employees 1001-5000
← All annual reports
FY2024 Annual Report · Option Care Health
Sign in to download
Loading PDF…
Providing Extraordinary Care
that Changes Lives
2024 ANNUAL REPORT

Clinical excellence 
infused with
compassionate 
care.
Fellow Stockholders,
Best regards,
John C. Rademacher
Every year we are defined by our challenges and opportunities. In 2024, we unexpectedly
faced significant hurricanes, supplier shortages and a cyberattack on one of healthcare’s
major claims processors. Through it all, we persevered. I’m proud of how our team overcame
these challenges, while continuing to execute at a high-level, drive growth, and emerge stronger.
Our resilience and keen focus on our patients also helped us capitalize on market opportunities
and elevate the extraordinary care we provide. Our team of more than 8,000 dedicated members—
approximately 5,000 of whom are clinicians—came together as One Team with One Goal to serve
more than 285,000 unique patients and their families.1
Thanks to the tremendous efforts of these team members, we ended the year with strong financial
performance. We delivered 16% net revenue growth, generated more than $320 million in operating
cash flow and deployed approximately $285 million in capital expenditures, acquisitions and share
repurchases, to help drive value for our stockholders.
In addition to our financial performance, we advanced our strategic priorities and initiatives with
the following accomplishments:
In addition, we are an organization that requires extraordinary people to provide extraordinary care
and have built a culture that attracts and retains the best and brightest talent. One of our core
values is ‘We are passionate about people’ and we bring that to life by making significant
investments in our team members’ development and growth. These investments were recognized
once again with the Gallup® Exceptional Workplace Award and Military Friendly® Employer
designation.
As we look to 2025, our mission to transform healthcare by providing innovative services that
improve outcomes, reduce costs, and deliver hope for patients and families continues to be our
guiding light. To fulfill this mission, we are focused on providing hope to even more patients. I look
forward to growing, thriving, and making a significant impact on our organization, in our
communities and with our patients.
   Data on file, Option Care Health
1
Option Care Health is the largest indepen-
dent provider of infusion therapy in the 
nation. For the past 45+ years, we have 
delivered cutting-edge infusion therapies, 
nursing support and seamless transitional 
care for patients of all ages in their homes 
or in one of more than 170 infusion 
locations including 15 sites with advanced 
practitioner capabilities.
Through our long-term partnerships with 
payers, biopharmaceutical manufacturers, 
healthcare systems, physicians and other 
referral sources, we deliver infusion 
therapies and services across a wide range 
of acute and chronic conditions. However, 
the relationships that truly drive our 
commitment to clinical excellence are those 
between our team of more than 5,000 
clinicians and the patients they serve.
•  We invested more than $35 million to improve our facilities, including opening
state-of-the-art care management centers in New York City and Tampa, Florida as well as
upgrading locations across our network. We now have over 170 infusion suite locations
with over 700 chairs nationwide.
•  We improved the patient experience by reducing onboarding time in both acute and chronic
sectors, expanding our services to encompass the launch of new products within rare
and orphan and other novel treatments and extending access to key therapies for tens of
millions of patients.
•  We strengthened our technology platform to improve reliability and minimize disruptions
while partnering with Palantir and others to enhance efficiency, quality, and
team effectiveness.
•  We bolstered our infusion pharmacy and clinic presence in South Carolina through our
acquisition of Intramed Plus, which closed in January 2025.
•  We leveraged data analytics, automation, machine learning, and artificial intelligence to help
streamline operations, reduce waste, accelerate cash collections, and enhance value for
our stakeholders.

(!'&''&
&(%'&!+!"  &&"!
*->4593?:9

:=8

 -=6"91

!!(%#"%'#(%&(!''"&'"!
"%0"'&(%'&+!'"

:=?4125>/-7D1-=190101/18.1=


"%

'%!&'"!%#"%'#(%&(!''"&'"!
"%0"'&(%'&+!'"

:=?41?=-9>5?5:9;1=5:02=:8?:
:885>>5:925719@8.1=


"#'"!%'!
<%'82%1)3*6)+-786%28%774)'-*-)(-2-87',%68)6
17-B-=1



 8%8)3638,)6.96-7(-'8-323*-2'36436%8-323636+%2->%8-32
 1403=)6()28-*-'%8-323



-61>501=&@5?1

!-99:/6.@=9



((6)773*46-2'-4%0)<)'98-:)3**-')7
$-43()
%135>?=-9?H>?171;4:919@8.1=59/7@0593-=1-/:01



&1/@=5?51>=135>?1=10;@=>@-9??:&1/?5:9.:2?41/?
'5?71:21-/4/7->>
'=-0593&D8.:7
!-81:21-/41C/4-931:9B45/4=135>?1=10
B@@BA-GB6>
C4EI4?H8C8EF;4E8
)*"
(4F74D!?B54?-8?86G'4E>8G
&1/@=5?51>=135>?1=10;@=>@-9??:&1/?5:93:2?41/?!:91
#A7<64G85L6;86>@4E><9G;8E8:ABJAF84FBA87@4E><9G;8E8:@4E>J;8G;8EG;8E8:@4E>J;8G;8EG;8E8:@4E>J;8G;8EG;8E8:@4E><9G;8E8:@4E>J;8G;8EG;8E8:@4E>J;8G;8EG;89@4E>J;8G;8E4ALB9G;BF88EEBE6BEE86G@4E>J;8G;8EG;8E8:8GI4?H8B9G;8E8:;8?75LABA499BAG;8(4F74D!?B54?-8?86G'4E>8GBAFH6;74G8
FB9 85EH4ELG;8E8J8E8F;4E8FB9G;8E8:BHGFG4A7;B?78EF GB 58 9 46GBEF

#G8@
/AE8FB?I87-G499B@@8AGF

#G8@
L58EF86HE8G9BE,8:;B?78E'4GG8EF4A7#FFH8E*HE6;4F8FB9DH8G,

#G8@
 ;B?78E'4GG8EF

#G8@
8EG4
.;F4A7HA68EG4 46GBEFT

#AI8FGBEF4E864HGF
4A7HA68EG4BA?L4FB9G;874G8G;8L4E8@478
K68CG4F
E8DH8B9?B64G
J8;B?78EF4F9B??BJF
F
$7,(176.;8B@C4AL<@CEBI8FC4G<8AGFUDH4?GB@4A4:8C4G<8AGF46EBFFG;86BAG8L@8GE<6FG;4GG<8546>GBJ;4G@BFGC4L8EF@BA
.;8B@C4ALB99H??F8EI<68C;4E@46<8F4A7FG4A74?BA8
4@5H?4GBEL864A68E4A7:4FGEB
00812*/2%8/,11)86,21.;8B@C4ALB998EF8KC8EG
+521,&1)/$00$725<,625'(56.;8B@C4ALGE84GF6;EBA<6
(852/2*,&$/,625'(56.;8B@C4ALCEBI<78F4A4EE4LB9GE84G@8AGFGB@4A4:8G;8CEB:E8FFFJ
$9(1($/7+.;8B@C4ALB998EF4A4G4A76?
CE8:A4A6<8F
*8EFBA4?B9FH56BAGE46G87AHEF-90 -=61?593
.;8B@C4ALUFF4?8F4A7@4E>8G8G8G9BE6BAGE46GFJ8G8G)CGH@,K4A7)EF8GF?<68AF8F4A7F8EI<68@4E>F
.;8B@C4ALCHE6;4F8FC;4E@468HG<64?F4A7@87<64?FHCC?<8F7
.;8B@C4AL:8A8E4G8F@BFGB9221/?593=@3#=5/1>
*E<6F'87<-C4A,$
"84?G;4A7G;88AG8EF9BE'87<64E8'87<64<7-8EI<68FS'-T4A7G;858A6;@4E>E8<@5HEF8@8AGI4E<8F5LC4L8E
6BAGE46G
.;8@BFG6B@@BA?LHF8758A6;@4E>F4E81*4A7-*
1*F@4L;4I84F<:A<9<64AG<@C46GBAG;8CEB9:EBHA76;86>FBA8@C?BL88F
4A7G4>8FFG8CFGB8AFHE8G;4G88CABJA4FSCEBG86G87;84?G;
8A4A78FG8CFGB
8AFHE84:546>-G4GHG8CEB;<5ABJ546>-G4GHG8546>-G4GHG878F6E<58745BI8
0ABJABJABJ?8FF7&4J8K8@CGF68EG48G;8AG<
%<6>546>-G4GHG8HA78EJ;<6;4A46G&4J
#A477
&4J@4ALB9G;8FG4G8F&4JJ;&4J4A74AL4CC?<645?8FG4G8F8?9E898EE4??4JF
.;89878E4?-G4E>&4J:8A8E4??LCEB;<5ABJFBEF;BH?7>ABJ&4J
-H6;C8EFBAFBE8AG&4J
@8-9-;5?-7%1>:@=/1>
.;8B@C4ALUF@ABJ?87:84A7F>4A7FH668FF
03/2<((1*$*(0(17.;8B@C4AL58?<8I8FG;4G;<:;?L8A:4:87G84@@8@58EF78?
($/7+$1'"(//%(,1*.;8B@C4ALCEBI<78F4;B?9BE68J:EBHA7F8KC8E<8A68F4A7
I<8JCB8FHFFGEBA:8E@BE8C?468J;8E8G84@@8@58EF988?I4?H87E8FC86G874A78@CBJ8E87GB6BAGE<5HG8G;8C?468FHCCBEGFG;878I8?BC@8AG4A7FH668FFB94??G84@@8@58EF
11

.;8B@C4ALE8?<8FBAC?468J;8E8G84@@8@58EF988?I4?H874A7
FHCCBEG87G;EBH:;8F<78E5HEA#&
.;8
B@C4AL@4946GBEF
:8;-9D&;1/525/%5>6-/?:=>
855(9(18($1'352),7$%,/,7<:,//'(&/,1(,)7+(3+$50$&(87,&$/,1'8675<81'(5*2(6&(57$,1&+$1*(6,1&/8',1*/,0,7,1*
25',6&217,18,1*5(6($5&+'(9(/230(17352'8&7,21$1'0$5.(7,1*2)7+(3+$50$&(87,&$/67+$7$5(&203$7,%/(:,7+7+(
6(59,&(6:(3529,'(
)HE5HF8G
C;4E@468HG<64?FG;4G4E86B@C4G<5?8J8G9BE
C;4E@468HG<64?FG;4G4E86B@C4G<5?8JGB?<@88CG;8FGB8FG45?F
*H5?<64GJ4F8KC86G87GB684F84A7'87<-C4AG;F
"BJ8I8E'87<-C4A6BAG4A7;4F5HG
G;8E8
18G68EG48GG;8F8CEB7H6GF
?G;BH:;J858?<8I8J864A89986G88CF498GLFGB6>GB8AFHE86BAG8GF
F4E8FH?GJ84E8B9G8AE8DH8GF4:8FG;4ABE<:8GF
J;8E8FH6;F;BEG4:8F7BABG8K8?LG;4AABG?8FFG;4AG;864EEL8GC?46894546>-G4GHG84A794?F86?4<@F?4JFGE478E8:H?4G89986G$4AH4EL
#A4778AFG8CFGBE87H686BI8E4:84A7BE8AEB??'87<64<7E868?L6BAGF
4FFB6<4G87J?B:4A7E8FH@87ABE@4?5FBE
P
74@4:8GBBHE5HF8GF
.;8F8E8FH?GF6BH?7;4I84@4G8E<4?47I8EF889986GBABHE5HFB9E8:H?4GBEL46GABJA4FG;8EH:-HCC?L;44A7GE468E8DH4:8EF4A774:84A7GE4AF46G6>%17-?593?:"@=901.?1091>>
85(;,67,1*,1'(%7('1(66&28/'$'9(56(/<$))(&7285%86,1(66$1'*52:7+35263(&76
FB9868@58EJ8;47
@ABJJ;8G;8EJ8J84ALB9
G;8F846G8G;8F8C4L@8AGF78C8A7FBABHE9F
78F6E<58745BI8
20

"(0$<127%($%/(72*(1(5$7(68)),&,(17&$6+)/2:726(59,&($//2)285,1'(%7('1(66$1'0$<%()25&('727$.(27+(5
$&7,216726$7,6)<2852%/,*$7,21681'(568&+,1'(%7('1(66:+,&+0$<127%(68&&(66)8/
)HE458F6;87H?87C4L@8AGFBEGBE898C4L@8AGFB9
8?LE8FH?G477GBE8FGEH6GHE8BEE896>%17-?593?:"@=:88:9&?:/6
529,6,2162)285&25325$7(*29(51$1&('2&80(176&28/'0$.($1$&48,6,7,212)86025(',)),&8/7$1'0$<35(9(17
$77(0376%<285672&.+2/'(56725(3/$&(255(029(285&855(170$1$*(0(17(9(1,),7,6%(1(),&,$/72285672&.+2/'(56
)HEG;8;B?78EF
@BA:BG;8EG;G;8G8E@FB9J;<6;@4L588FG45?;B?78E4CCEBI4?4A7J;<6;@4L;B?78EF
P
CEBI<78G;4G78AG;B?78E46G;B?78EFJ8AG84A7?<@
857+,5'$0(1'('$1'5(67$7('&(57,),&$7(2),1&25325$7,21'(6,*1$7(67+(28572)+$1&(5<2)7+(7$7(2)(/$:$5(
$67+((;&/86,9()2580)25&(57$,1/,7,*$7,217+$70$<%(,1,7,$7('%<285672&.+2/'(56:+,&+&28/'/,0,7285672&.+2/'(56A
$%,/,7<722%7$,1$)$925$%/(-8',&,$/)2580)25',6387(6:,7+86
*HEFH4AGGBBHEG;;B?78EFGBHFBEBHEFGB6>;B?78EF<<<4AL46G;B?78EFU45
)HE
B4E7B9
4A7GB9;B?78EF
)HECE898EE87FGB6>6BH?758
.;8CBG8AG<4?@4L78?4LBECE8I8AG46;4A:84G4CE8@8GCE<684A7@4G8E<4??L4A747I8EF8?L49986G8GCE<684A7G;8IBG
22

"(&$1127*8$5$17((7+$7285672&.5(385&+$6(352*5$0:,//%()8//<,03/(0(17('257+$7,7:,//(1+$1&(/21*7(50
672&.+2/'(59$/8(
1864AABG:H4E4AG88G;4GBHEFGB6>E8CHE6;4F8CEB:E4@J;B?78EI4?H8
#A$4AH4ELG;8B4E7B9E8CHE6;4F8CEB:E4@4HG;BE
.;8E8CHE6;4F8CEB:E4@7B8FABG;4I84A8KC4G94IBE45?8CE<68F
.;8E8CHE6;4F8CEB:E4@@4L58FHFC8A787BEG8E@;B?78EI4?H8
23

191=-7%5>6-/?:=>
(1',1*$1')8785(/,7,*$7,21&28/'68%-(&786726,*1,),&$17021(7$5<'$0$*(6$1'255(48,5(8672&+$1*(285
%86,1(6635$&7,&(6
188@C?BLC;4E@46FE8?4G;B?78EFH8
@4G8E<4?6;4A:8FGBBHE5HFB96?4<@F?BFF8F4A7CBG8AG<4?
?4JFH8?LGBB66HEF
FH668FF9H?CEB7H6GBECEB98FF8EFU6B@C8AF4G
9EB@C4G<8AGFBEG;87FABJA@4G8E<4??<458L8@C?BL88FB946DHF78F6E<58745BI8
#9G;8F8BE74@4:8
.;8B@C4ALE8?<8FBAF6BH?76B@CEB@FBE
HAABJA
4GG46>FBABHEF6BH?7ABGB66HE
?G;BH:;J8;4I8G4>8AFG8CFGBCEBG86GG;8
F86HEF
-86HEF5L;46>8EF4A7F<@88CC468JF
4A7?<45F
#GFE8?4G87GBG;8HF8B9#4A7
6;4A:8F8G78@4A74A74668CG4A68B9#G86;AB?B:<8F4E8HA68EG4B99E4H74A7GBBC8E4G8FH668FF9H??L
AL94A8FF8FBE@4G8E<4?@86BEE86G8?LE8FH?G8GCE<68B9BHEFGB6>4A7B9CE8F6E<58EFCEBI<78EF
C4G<8AGF4A79468LFHCC?<8EFBEI8A7BEF78G@84FHE8FGB477E8FF6?<@4G86;4A:86BH?747I8EF8?L49986GBHE5HFJ6 -9-31819?-90&?=-?13D
18;4I878I8?BC874A7<@C?8@8AG8746L58EF86HE78F<:A87GB<78AG<9L78G86GCEBG86GE8FCBA7GB4A7
E86BI8E9EB@EFFG8@@HF
54F874CCEB46;
.;89E4@8JBE>4?G;BH:;G;
774A778F<:A87GBCEBG86GG;86BA9<78AG<4?F
18;4I846L58EF86HE@4A4:8@8AG68AG8EFBA:BI8EA4A68C8BC?8CEB68FF8F4A7G86;AB?B:L
18
CEBI<78F86HEF9EB@6L58EF86HEFJ@4A4:8@8AG9E4@8JBE>
.;8LE
B@@F4A7BI8EF88FE@F9EB@>ABJA6L58EF86HE 46GBEFT9BE@BE8F
27

:A1=9-9/1
.;8+H4?
F
C4EGB9F4A7<@C?8@8AG6BAGEB?F4F4CCEBCE<4G84A7984F<5?8GB@F
.;8#-)
4?FBFHC8EIF4A78;B?78EF
)HE#-)FG;E84GF4A78F<78E5HEA#&
)HEBG;8ECEBC8EG<8F@4C4EI4?H8
C8EF;4E88GHA78EG;8FL@5B?
S)*"T
:701=>:2%1/:=0
FB9 85EH4ELG;8E8J8E8FGB6>;B?78EFB9E86BE7B9BHEB@@BA-GB6>
5A50190#:75/D
18;4I8A8I8EC4<764F;74A77BABG4AG<6@?4:=5E102:=>>@-9/1@901=<@5?D:8;19>-?5:9#7-9>
-88#G8@
S-86HE;B?78E'4GG8EFTB9G;?1=10&1/@=5?51>-90(>1:2#=:/110>
668(585&+$6(62)48,7<(&85,7,(6
)A 85EH4ELG;8B@C4ALUFB4E7B9B9G;8B@C4AL
)A868@58EG;8B@C4ALUFB4E7B9E8CHE6;4F8CEB:E4@4HG;BE9EB@
)6GB58EG;EBH:;868@58E
#1=5:0
':?-7!@8.1=:2
&4-=1>#@=/4->10
A1=-31#=5/1#-50
;1=&4-=1
':?-7!@8.1=:2
&4-=1>#@=/4->10
->#-=?:2#@.75/7D
99:@9/10#7-9>
:=#=:3=-8>
;;=:C58-?1
:77-=)-7@1:2
&4-=1>'4-? -D
,1?1#@=/4->10
(901=?41#7-9>:=
#=:3=-8>
)6GB58E)6GB58E
R

R

R


(BI8@58E(BI8@58E









868@58E868@58E








R








R
#A$4AH4ELG;8B4E7B9E8CHE6;4F8CEB:E4@4HG;BE
29

&?:/6#1=2:=8-9/1=-;4
.;89B??BJ4A7846;BE8LABJA4A7HA>ABJAEFHA68EG4FHA68EG4
 46GBEFT591>>"A1=A51B
)CGB9?B64GJ1/@=5?D9/5019?
FCE8I876BAGF7H8GBG;8L
4CC?<64G5?5:9:2%1>@7?>:2";1=-?5:9>
.;89B??BJG;4GG;8LJ8EF78G%8-32<4)27)8CE86<4G)(377%-232%7,03;)(+))83*2'31)!%<)2)*-8<4)27)
;4A:8@7?>:2";1=-?5:9>
.;89B??BJ-90>1C/1;?2:=;1=/19?-31>
(8GE8I8AH8








BFGB9E8I8AH8








!EBFFCEB9-90>1C/1;?2:=;1=/19?-31>
-8??-90>1C/1;?2:=;1=/19?-31>
#AG8E8FG8KC8AF8A8G

 
 



DH-90>1C/1;?2:=;1=/19?-31>
#A6B@8G4K8KC8AF8








.;8B@C4ALE86BE787-90>1C/1;?2:=;1=/19?-31>
(8G8GI4?H8B9G;8
@:@=/1>
 BEG;8L84EF8A787868@58E4A7G;8B@C4ALUFCE<@4ELFBHE68FB9?8LC4EGB9BHE:EBJG;FGE4G8:L
.;8B@C4AL
;8CE8,8IB?I-90>
(8G64F;CEBI<7875LBC8E4G7HE
40

=5?5/-7//:@9?593>?58-?1>
.;8B@C4ALCE8C4E8F88FG<@4G8F4A74FFH@CGG;4GG;8LJB9
E86BI8EL7H8GBABGE868F
58GJ88AG;874G8B9F8EI<684A7588FG<@4G8F4A74FFH@CG?%-?1%5>6
.;8B@C4ALUFCE<@4EL@4E>8GE8KCBFHE8G;8B@C4AL;4FHG8G?1=10#@.75///:@9?5935=8
.BG;8-GB6>;B?78EF4A7B4E7B9;B?78EFU8DHFB9@4G8E<4?@F
-H6;
CEB687HE8F8A4F4J;B?84A7J84E8ABG5L6B@@HA<64GABJ?87:8J;B
4FF
C4EI4?H8F;4E8F4HG;BE
C4EI4?H8F;4E8F4HG;BE4A7F;4E8FBHGFG4A7;B?78EFU8DH54F8754F876B@C8AF4G4A7E8?4G878K6@=D
&?:/6
#-5059
-;5?-7
%1?-5910
-=9593>
//@8@7-?
10"?41=
:8;=1419
>5A19/:81
:>>
':?-7
&?:/64:701
=>H<@5?D
4?4A68868@58E

R



  



  
-GB6>54F87BCG4A7E8?4G87
G4KJ54F87BCG4A7E8?4G87
G4KJ4A7
E8?4G87G4K89986GF

R

R

 
R

R

R


(8G54F87BCG4A7E8?4G87
G4KJ4A7
E8?4G87G4K89986GF

R

R

 
R

R

R


(8G591>>R.;8B@C4ALUFFGB6>8G4FB9
868@58E
HEJ;<6;E8FH?G87B99H??F8EI<68C;4E@46<8F4A7FG4A74?BA84@5H?4GBEL5>:2#=1>19?-?5:9R.;8466B@C4AL868EG4:2:9>:750-?5:9R.;8B@C4ALUF6BAFB?<74G8794-90->4<@5A-719?>R.;8B@C4AL6BAF<78EF4??;<:;?L?8G9HA7F
//:@9?>%1/15A-.71R.;8B@C4ALUF466BHAGFE868B9
E86BI8EL7H8GBABGE868F58GJ88AG;874G8B9F8EI<684A7
5R#AI8AGBE<8FJ;<6;6BAF1>-90"?41=@==19?>>1?>R#A6?H7871>R.;8B@C4AL;4F?84F84:E88@8AGF9BE946>1?>#=:;1=?D-90<@5;819?-90%121==-7&:@=/1>R!BB7JFA4@8F;4I84HF89H??<98E4A:?819?>R.;8B@C4ALUF?=@819?>R.;8B@C4ALHF8F78E@4A4:8@8AGB5=86GG;4GG;8LJ?:2%1A19@1RBFGB9E8I8AH86BAF?=-?5A1C;19>1>R-8??8G109/19?5A1:8;19>-?5:9R.;8B@C4AL466BHAGF9BEFGB6>54F8754F87BCG
-6;B?8FBCGHABAG;8:E4AG74G8
 BE4J4E7FJ591>>/<@5>5?5:9>R.;8B@C4AL466BHAGF9BE5HFR.;8B@C4AL466BHAGF9BEG4K54F8?LG;4AABGG;4GFB@8
CBEG8?LG;4AABGGB58E84?8?LG;4AABGGB58FHFG48?LG;4AABG54F87BA6H@H?4G:2@>591>>%5>6R.;8B@C4AL:8A8E4G8FE8I8AH89EB@@4A4:8764E86BAGE46GF4A7BG;8E4:E88@8AGF
JE8?4G@=1819?>R.;8949BE@84FHE8G54F87@84FHE8@8AGG;4GF;BH?75878G8E@8GC4EG<68GC4EG<68G74G4FBHE68F
/AB5F8EI45?88GC4EG<68GF9BE<78AG<64?4FF8GFBE?<458GF9BEF<@8GFG;4G4E8ABG46G8GC4EG<6>@10//:@9?593#=:9:@9/1819?>R#A(BI8@58EG;8 -F4A7G4KC?4AAD>9/ G)A'4LG;8B@C4AL8AG8E87GB@87;B?78EFJ;<6;
JBH?7E8FH?G;B?78EF;B?7;5=-?:=D'41=-;D>>1?&-71G.;8B@C4AL6?BF87G;8GE4AF46G?1=:8192@>5:99/G#AH:HFGCHEFH4AGGBG;8FGB6>CHE6;4F84:E88@8AG74G87$HA8G;8
B@C4AL6B@C?8G87G;846DH593!1?B:=69/G#ACE#A6

S-*((T9BE4CHE6;4F8CE<68A8GB964F;46DHC?4A4A7@4G6;8FB98@C?BL886BAGE<5HG8?LG;4AABGG;4GFB@8
CBEG8?LG;4AABGG;4GFB@8BE4??G;87898EE87G4K4FF8GFJ4A764EEL9BEJ4E7C8E
1>/=5;?5:9
-7-9/1-?
13599593:2
#1=5:0
4-=31019125?
?::>?>-90
C;19>1>
4-=31019125?
?:"?41=//:@9?>
-7-9/1-?90:2
#1=5:0
04?H4G
4F<684EABHGFG4A7BHGFG4A78DHBCG4J4E7F4A7C8E9BE@4A68FGB6>HA8DH8DHBCG4J4E7F



*8E9BE@4A68FGB6>HA;1=:88:9&4-=1
4EA;1=:88:9&4-=1
4EA/-7,1-=90101/18.1=

 5958@8#-D819?>











4A758LBA7

.BG4??84F8C4L@8AGF

&8FF8?LG;4AABGE87H68G;8948LC8EFBAA8?46;4A:88?<;BB7G;4G4E8CBEG8?LG;4AABGG;4GG;8948G6BAF<78E4GCE<68
.;8B@C4AL78G8E@8F<:A<9<64AG
8FG<@4G8F4A74FFH@CGFA4@8F



)G;8E4@BEGFA4@8F

 

)G;8E4@BEG/:@9?
1.?>>@-9/1
:>?>
!1?-7-9/1
,8IB?I8E 46/:@9?
1.?>>@-9/1
:>?>
!1?-7-9/1
,8IB?I8E 46FH5=86GGB68EG4/-7,1-=90101/18.1=

 5958@8#-D819?>











.BG4?


HE?=@819?
-==D593)-7@1->
:21/18.1=



 -=61?>2:=
019?5/-7?18
1A17
&539525/-9?"?41=
".>1=A-.719;@?>
1A17
&539525/-9?
(9:.>1=A-.71
9;@?>1A17

 
/F8B978EFFH6;4F@4E>8G4A76E87F
'4E>8GEE8CE8F8AGFG;8CBFF<5E8?4G87GB478E
E87
4FFB6<4G87J59>>1?#:>5?5:9
1=5A-?5A1
-7-9/1&411?-;?5:9
1/18.1=


1/18.1=


#AG8E8FGE4G864C78F<:A4G874F64F;9?BJF;87:8
*E8C4<78KC8AF8F4A7BG;8E6HEE8AG4FF8GF




#AG8E8FGE4G864C78F<:A4G874F64F;9?BJF;87:8
)G;8EABA6HEE8AG4FF8GF



.BG4?78E8GCE<68F8GF9BE
<78AG<64?4FF8GFBE?<458G
C4EG<68EDHBG8BAG;8?B4AF8EDHBG8&8I8?8G4A79HGHE8
8KC86G4G8EF
-88(BG8)6-:%8-:)278691)2879BE9HEG;8E78G9HA7FR/A78EG;8B@C4ALUFDH;B?78EFBA'4LG;8B@C4AL@4LBCGBCG4CCE86<4GHA:E4AGF4A7C8E9BE@4A68HA8L8@C?BL88F4A7
74HG;BEJ8E84HG;BER)CG8GI4?H8BAG;874G8B9:E4AG4A74E88K8E6BCGBCGBCG-6;B?8FCE<69E88BCG
*1534?10A1=-31
C1=/5>1#=5/1
33=13-?19?=59>5/
)-7@1?4:@>-90>
*1534?10A1=-31
%18-59593
:9?=-/?@-7521
4?4A684G868@58E







!E4AG87
R

R

R
K8E6BCGBCGBCGBCG"@?>?-90593
";?5:9>C1=/5>-.71
%-931:2";?5:9
C1=/5>1#=5/1
"@?>?-90593
";?5:9>
*1534?10A1=-31
C1=/5>1#=5/1
*1534?10A1=-31
%18-59593
:9?=-/?@-7521
";?5:9>
C1=/5>-.71
*1534?10A1=-31
C1=/5>1#=5/1



























































??BCG?=5/?10&?:/6R,8FGE<6G87FGB6>:E4AGFFH5=86GFB?8?LGB4A8@C?BL88UF6BAG:E4AGFFH5=86GFB?8?LGB4
4J4E7FB9
@BAG;874G8B9
G;8:E4AG
FH@@4ELB9E8FGE<6G87FGB6>4J4E746G?=5/?10&?:/6
*1534?10A1=-31
=-9?-?1-5=
)-7@1
4?4A684G868@58E





!E4AG87





08FG874A74J4E7FJ4J4E7FG;4G4J4E7FI8FG877HER*8E9BE@4A6854F87FGB6>HA8G6?BF8
BAG;8:E4AG74G8
B@C8AF4GHA
F
B9868@58E"#AB?BA:8E;8?7F;4E8FB9G;8B@C4ALUF6B@@BAFGB6>

*-==-9?>R*E
.;814EE4AGF;4I84L84EG8E@4A74A
8K8E6E8FC86GE8FC86GR*E14EE4AG:E88@8AG74G87
4FB9'4E6;J;<6;8AG
.;814EE4AGF;4I84
L84EG8E@4A7;4I88K8E6
HE
HEE8FC86G1#=:3=-8R)A 85EH4ELG;8B@C4ALUFB4E7B9B9G;8B@C4AL
)A868@58EG;8B@C4ALUFB4E7
B98G6BA79BE4A4I8E4:8F;4E8CE<68B9
4A7
GBG4?
FB9868@58EG;8B@C4AL6B@C?8G87F;4E8E8CHE6;4F8FHA78EE8CHE6;4F8
CEB:E4@
.;"@?>?-90593R.;89B??BJ9BEG;8L84EF8A787
868@58E4A7@=D&?:/6RFB9868@58E4A7G;8B@C4AL;8?74A7F;4E8FB9GE84FHEL
FGB6>E8FC86GBHGFG4A7-/?5:9>B5?4<@5?D 1?4:09A1>?11>R.;8B@C4ALCEBI<78F@4A4:8@8AGF8EI<68FGB13=11819?R)A 85EH4ELJ88AG8E87G;8A;8?75L"#4GG;8F4@8CHE6;4F8CE<68C8EF;4E84FG;8HA78EJE;8?75L"#
)A'4E6;G;8GE4AF46G
& !'%#"%'!
.;8B@C4AL;4F47BCG87-/ )+1)28)4368-2+!34-'	
1463:)1)28783)4368%&0) )+1)28
-7'03796)74A7;4FE8I8ES)'T
.;8)'HF8FA8G87864:/7:>@=1:9?=:7>-90#=:/10@=1>
4F87BA4A8I4?H4GG;4G6BAGEB?F@4L
586B@8599?1=9-7:9?=:7"A1=59-9/5-7%1;:=?593
.;8E8;4F588AAB6;4A:87HE8?L
GB@4G8E<4??L49986GBHE?1=10#@.75///:@9?5935=8
.BG;8-GB6>;B?78EF4A7B4E7B9;B?78EFU8DHG;4G4@4G8E<4?J84>A8FF8K
)HE4H7G;4G6BAGEB?F@4L586B@8-901=?-59"?41='=-0593==-931819?>
(B7;B?78EF
?18
;(&87,9(203(16$7,21
.;8;B?78EF
?18
(&85,7<:1(56+,32)(57$,1(1(),&,$/:1(56$1'$1$*(0(17$1'(/$7('72&.+2/'(5$77(56
.;8;B?78EF
?18

(57$,1(/$7,216+,36$1'(/$7(' 5$16$&7,216$1',5(&7251'(3(1'(1&(
.;8;B?78EF
?18
5,1&,3$/
&&2817$17((6$1'(59,&(6
.;8;B?78EF
78

#%')
?18
;+,%,76$1',1$1&,$/7$7(0(17&+('8/(6
#-31
-59-9/5-7&?-?1819?>
.;89B??BJ;B?78EFUDH
901C?:C45.5?>
C45.5?
!@8.1=
1>/=5;?5:9


.;14EE4AG:E88@8AG74G87$H?L5L4A758GJ88A.E4AF98E
.EHFGB@C4AL&&HE4.EHFGB@C4AL&&4FGEHFG8844B9@8E<64(

)CG/A/A/A;B?78EFUDH54F8B6H@8AG

 
2,&.4KBAB@LKG8AF54F8B6H@8AG

&
2,&.4KBAB@LKG8AF54F8B6H@8AG

*,
2,&.4KBAB@LKG8AF54F8B6H@8AG

2,& BE@4GG87BI8E*4:8
N
8F<:A4G8FG;8B@C4ALUF@4A4:8@8AG6BAGE46GFBE6B@C8AF4GBELC?4ABE4EE4A:8@8AG

8EG4	 5/4-17&4-;5=:
'<6;48?-;4C
-?1
F$B;A
,478@46;8E
$B;A
,478@46;8E
;<89K86HG@4AA
(4G4F;486>@4AA